The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Management of transaminase elevations in patients receiving idelalisib.
 
William G. Wierda
Consulting or Advisory Role - Abbvie; Celgene; Emergent BioSolutions; Genentech/Roche; Genzyme; Gilead Sciences; GlaxoSmithKline/Novartis; Merck; Pharmacyclics; Sanofi
Research Funding - Abbvie; Acerta Pharma; Emergent BioSolutions; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Pharmacyclics
 
Steven Coutre
Stock and Other Ownership Interests - Pharmacyclics (I)
Honoraria - Gilead Sciences
Consulting or Advisory Role - Abbvie; Celgene; Genentech/Roche; Gilead Sciences; Janssen Oncology; Novartis; Pharmacyclics
Research Funding - Abbvie (Inst); Celgene (Inst); Gilead Sciences (Inst); Novartis (Inst); Pharmacyclics (Inst)
Travel, Accommodations, Expenses - abbvie; Celgene; Gilead Sciences; Janssen Oncology; Novartis; Pharmacyclics
 
Ian Flinn
Stock and Other Ownership Interests - RainTree Oncology Services
Research Funding - Acerta Pharma (Inst); Agios (Inst); Calithera Biosciences (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunogen (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); TG Therapeutics (Inst); Trillium Therapeutics (Inst)
 
Ajay K. Gopal
Honoraria - Gilead Sciences; Janssen Oncology; Millennium; Pfizer; Seagen
Consulting or Advisory Role - Gilead Sciences; Janssen Oncology; Millennium; Pfizer; Seagen
Speakers' Bureau - Seagen
Research Funding - Abraxis BioScience (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Piramal Life Science (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Teva (Inst)
 
Susan Mary O'Brien
Honoraria - Amgen; Celgene; Gilead Sciences; Janssen; Pfizer; Pharmacyclics; ProNAi; Regeneron
Consulting or Advisory Role - Amgen; Celgene; CLL Global Research Foundation
Research Funding - Acerta Pharma; Gilead Sciences; Regeneron
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen; Regeneron
 
Gilles A. Salles
Honoraria - Amgen; Mundipharma; Roche/Genentech
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Mundipharma; Novartis; Roche/Genentech
Research Funding - Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Andrew David Zelenetz
No Relationships to Disclose
 
Terry Newcomb
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Christopher C Waldapfel
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Wei Ye
Employment - Gilead Sciences
 
Paolo Ghia
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences; GlaxoSmithKline